The advances in targeted therapy and immunotherapy for glioblastoma: Basic research and clinical trials
Glioblastoma (GBM) is the most common and fatal type of malignant central nervous system tumor with high invasion. The median overall survival of GBM is only around 14 months by standard treatment, which conventionally consists of surgical resection, followed by radiotherapy and adjuvant chemotherap...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Glioma |
| Subjects: | |
| Online Access: | http://www.jglioma.com/article.asp?issn=2589-6113;year=2018;volume=1;issue=3;spage=79;epage=88;aulast=Wang |